Please read this policy carefully to understand our policies and practices regarding your information and how we will treat it. If you do not agree with our policies and practices, your choice is not to use our Site.
YOU FURTHERMORE ACKNOWLEDGE AND AGREE THAT INDIVIOR IS NOT A MEDICAL PRACTICE AND DOES NOT PROVIDE MEDICAL ADVICE.
* * *
When we use these capitalized terms, they have the following definitions:
"Disclose" and variations such as "Disclosure" means any and all of the following: using, accessing or barring access, processing, fulfilling, disclosing, receiving, displaying, sharing, making available, transferring, storing, selling, leasing, licensing, retaining, deleting or destroying, combining, investigating, verifying, proving, enforcing and otherwise dealing with, voluntarily or involuntarily, personal information.
"Personal information," "personal information" or "PI" means information that we are required by law to protect and that: (a) personally identifies you, or (b) to the extent required by law, reasonably can be used specifically to identify you or your computing device.
Indivior will collect certain personal information that you provide to us voluntarily. For example, and not by limitation, we may collect personal information when you fill out a questionnaire, sign up for a survey or otherwise interact with us. Such information may include, but may not be limited to, your name, address and email address. In addition to providing you with the service or information you request on our Site, your PI may also be used to help us track the way you use our Site and our products.
When you provide Personal Information to us, we may ask if you want to receive future communication from us, such as newsletters, email or other information. You can choose not to receive this communication, if you wish, and you may opt-out by contacting us in response to the email you received.
Information may be shared with service providers who provide services for or administer activities on behalf of Indivior. Information you submit to one or more of the Indivior brands or bodies may be shared with another of the Indivior brands or bodies. Your Personal Information may also be shared with service providers who warehouse product, perform order fulfilment or provide hosting services. These companies have agreed to only use your information in the way we tell them and to have procedures in place to protect the information.
In the event Indivior, or its assets, is bought or sold, Personal Information may be included among the transferred business assets. In this case, a prominent notice on our Site of any change in ownership or uses of your Personal Information, as well as any choices you may have regarding your Personal Information will be provided.
Indivior may disclose specific Personal Information if it determines that such disclosure is necessary to comply with the law, such as to comply with a subpoena or to protect the safety of the public. When we believe in good faith that disclosure is necessary to protect our rights, protect your safety or the safety of others, or respond to a government request. This includes exchanging information with other companies and organizations for fraud protection and credit risk reduction.
We may provide information about you to service providers that perform certain functions or services on our behalf (for example, hosting our services, storing our data, managing databases, performing analyses, or sending communications for us). These companies are contractually limited in the ways in which they may use this information.Back to top
Technologies such as: cookies, beacons, tags and scripts are used by Indivior and our marketing partners, affiliates, or analytics or service providers. These technologies are used in analyzing trends, administering the Site, tracking users' movements around the Site and to gather demographic information about our user base as a whole. We may receive reports based on the use of these technologies by these companies on an individual as well as aggregated basis.
If you reject cookies, you may still use our Site, but your ability to use some features or areas of our site may be limited.
Indivior uses reasonable security techniques to help protect against the loss, misuse or alteration of information collected from you at an Indivior Site. When you transmit Personal Information, that information is stored on servers that Indivior has attempted to secure from unauthorized access or intrusion. Of course, no Internet site or service can be made 100 percent secure, and the Indivior Sites cannot be and are not responsible for unauthorized access to information by hackers who have obtained such access through illegal measures.
Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your Personal Information, we cannot guarantee the security of the Personal Information you transmit to our Site; any transmission is at your own risk.
While we cannot guarantee that loss, misuse or alteration to data will not occur, once we have received your information, we will make reasonable efforts to prevent such occurrences.
If you have submitted Personal Information through an Indivior Site or interactive advertisement, and would like that information modified, changed or deleted from our records, please click to provide us with your request and the email address you provided.
10710 Midlothian Turnpike
Richmond, VA 23235
Attn: Legal Department
If at any time you want to update, change or delete your information, you may log in to the Site where you have your information and make those changes on your profile page or you may contact us via email at Privacy@indivior.com. We will respond to your request to access within a reasonable time. If you do not want your PI collected, please do not submit it to us.
Please note that we do not maintain all PI in a form that can be accessed or updated by you and some PI may not be changed. Accordingly, and subject to applicable law, we will determine what may be accessed and how; we may also keep a record of changes (including deletions) and disclose them for lawful purposes.
We keep PI for as long as your account is active or as needed to provide you services and reserve the right to retain it to the full extent not prohibited by law (e.g., for the length of a statute of limitations). We may discard PI in our discretion, so you should retain your own records. Often it is not feasible or advisable actually to discard PI (such as commingled PI), so we reserve the right to retain and treat it as inactive or discarded (such as removing traditional "pointers" to it).
You may make a request for us to update eligible PI by writing to us at our Legal Notice Address. If applicable law requires us to accept requests by other means, use our address to obtain information about the other means. We will honour requests if required by law or if we determine in our sole discretion to do so. We may comply with qualified requests by supplying a copy or access to the relevant PI within a reasonable time, but no less time than is needed by us or others for processing or altering databases in the ordinary course of business. If we have a duty to require third-parties to delete or cease using PI, we may satisfy it by sending them notice to do so without further action (except as expressly required by law).
Copyright ©2017 Indivior PLC. All rights reserved.
SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) is a prescription medicine indicated for treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.
Treatment should be initiated under the direction of healthcare providers qualified under the Drug Addiction Treatment Act.
Do not take SUBOXONE Film if you are allergic to buprenorphine or naloxone as serious negative effects, including anaphylactic shock, have been reported.
SUBOXONE Film can be abused in a manner similar to other opioids, legal or illicit.
SUBOXONE Film contains buprenorphine, an opioid that can cause physical dependence with chronic use. Physical dependence is not the same as addiction. Your healthcare provider can tell you more about the difference between physical dependence and drug addiction. Do not stop taking SUBOXONE Film suddenly without talking to your healthcare provider. You could become sick with uncomfortable withdrawal symptoms because your body has become used to this medicine.
SUBOXONE Film can cause serious life-threatening breathing problems, overdose and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other medications that act on the nervous system (ie, sedatives, tranquilizers, or alcohol). It is extremely dangerous to take nonprescribed benzodiazepines or other medications that act on the nervous system while taking SUBOXONE Film.
You should not drink alcohol while taking SUBOXONE Film, as this can lead to loss of consciousness or even death.
Death has been reported in those who are not opioid dependent.
Your healthcare provider may monitor liver function before and during treatment.
SUBOXONE Film is not recommended in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, SUBOXONE Film may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone.
Keep SUBOXONE Film out of the sight and reach of children. Accidental or deliberate ingestion of SUBOXONE Film by a child can cause severe breathing problems and death.
Do not take SUBOXONE Film before the effects of other opioids (eg, heroin, hydrocodone, methadone, morphine, oxycodone) have subsided as you may experience withdrawal symptoms.
Injecting the SUBOXONE Film product may cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea, anxiety, sleep problems, and cravings.
Before taking SUBOXONE Film, tell your healthcare provider if you are pregnant or plan to become pregnant. If you are pregnant, tell your healthcare provider as withdrawal signs and symptoms should be monitored closely and the dose adjusted as necessary. If you are pregnant or become pregnant while taking SUBOXONE Film, alert your healthcare provider immediately and you should report it using the contact information provided below. *
Opioid‐dependent women on buprenorphine maintenance therapy may require additional analgesia during labor.
Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy, whether that use is medically-authorized or illicit. Unlike opioid withdrawal syndrome in adults, NOWS may be life-threatening if not recognized and treated in the neonate. Healthcare professionals should observe newborns for signs of NOWS and manage accordingly.
Before taking SUBOXONE Film, talk to your healthcare provider if you are breastfeeding or plan to breastfeed your baby. The active ingredients of SUBOXONE Film can pass into your breast milk. You and your healthcare provider should consider the development and health benefits of breastfeeding along with your clinical need for SUBOXONE Film and should also consider any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.
Do not drive, operate heavy machinery, or perform any other dangerous activities until you know how SUBOXONE Film affects you. Buprenorphine in SUBOXONE Film can cause drowsiness and slow reaction times during dose-adjustment periods.
Common side effects of SUBOXONE Film include nausea, vomiting, drug withdrawal syndrome, headache, sweating, numb mouth, constipation, painful tongue, redness of the mouth, intoxication (feeling lightheaded or drunk), disturbance in attention, irregular heartbeat, decrease in sleep, blurred vision, back pain, fainting, dizziness, and sleepiness.
This is not a complete list of potential adverse events associated with SUBOXONE Film. Please see full Prescribing Information for a complete list.
*To report pregnancy or side effects associated with taking SUBOXONE Film, please call 1-877-782-6966. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For more information about SUBOXONE Film, SUBOXONE® (buprenorphine and naloxone) Sublingual Tablets (CIII), or SUBUTEX® (buprenorphine) Sublingual Tablets (CIII), please see the respective full Prescribing Information and Medication Guide at www.suboxoneREMS.com.